Skip to content
6-K

Foreign Interim / Material

Altamira Therapeutics Ltd. CYTOF

0001213900-25-082071

← back to feed
Filed
Aug 29, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q2 2025 · Jun 30, 2025 5.02M sh
Shares Diluted Q2 2025 · Jun 30, 2024 2.06M sh
Operating Cash Flow Q2 2025 · Jun 30, 2025 −$1.38M
Operating Cash Flow Q2 2025 · Jun 30, 2024 −$3.2M
Cash And Equivalents Q2 2025 · Jun 30, 2025 $3.76K
Cash And Equivalents Q2 2025 · Dec 31, 2024 $998.62K
Cash And Equivalents Q2 2025 · Jun 30, 2024 $65.46K
Cash And Equivalents Q2 2025 · Dec 31, 2023 $733.7K
Current Liabilities Q2 2025 · Jun 30, 2025 $2.31M
Current Liabilities Q2 2025 · Dec 31, 2024 $1.16M
Current Assets Q2 2025 · Jun 30, 2025 $247.57K
Current Assets Q2 2025 · Dec 31, 2024 $1.54M
Total Assets Q2 2025 · Jun 30, 2025 $7.13M
Total Assets Q2 2025 · Dec 31, 2024 $8.65M
Eps Diluted Q2 2025 · Jun 30, 2025 −$0.31
Eps Diluted Q2 2025 · Jun 30, 2024 −$2.11
Eps Basic Q2 2025 · Jun 30, 2025 −$0.31
Eps Basic Q2 2025 · Jun 30, 2024 −$2.11
Operating Income Q2 2025 · Jun 30, 2025 −$2.63M
Operating Income Q2 2025 · Jun 30, 2024 −$3.92M